Jiangmen Hengjian Pharmaceutical Co. Ltd.

Primary Objective: This study used budesonide enteric-coated capsules (4 mg) manufactured and owned by Guangdong Hengjian Pharmaceutical Co., Ltd. as the test formulation, and budesonide enteric-coated capsules (4 mg, trade name: NEFECON®) owned by Everest Medicines (Singapore) Pte. Ltd. as the reference formulation, in accordance with relevant regulations for bioequivalence studies, to evaluate the bioequivalence of the test and reference formulations after administration in a fasting state. Secondary Objective: To observe the safety of the test formulation budesonide enteric-coated capsules and the reference formulation budesonide enteric-coated capsules (trade name: NEFECON®) in healthy trial participants.

Primary Objective: This study used budesonide enteric-coated capsules (4 mg) manufactured and owned by Guangdong Hengjian Pharmaceutical Co., Ltd. as the test formulation, and budesonide enteric-coated capsules (4 mg, trade name: NEFECON®) owned by Everest Medicines (Singapore) Pte. Ltd. as the reference formulation, to evaluate the bioequivalence of the test and reference formulations after administration in a postprandial state, in accordance with relevant regulations for bioequivalence studies. Secondary Objective: To observe the safety of the test and reference formulations, budesonide enteric-coated capsules (trade name: NEFECON®), in healthy trial participants.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsule (specification: 0.1g, license holder: Guangdong Hengjian Pharmaceutical Co., Ltd.) and the reference preparation norfloxacin tablet (specification: 0.1g, license holder: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsule and the reference preparation norfloxacin tablet in healthy subjects.